Cefoxitin: Single-agent treatment of mixed aerobic-anaerobic pelvic infections

Richard L Sweet, W. J. Ledger

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Cefoxitin (mefoxin), a new semisynthetic cephamycin antibiotic, is resistant to degradation by β-lactamase enzymes produced by bacteria. In vitro, cefoxitin is active against virtually all clinically important gram-negative facultative bacteria other than Pseudomonas and Enterobacter spp., gram-positive aerobic bacteria other than the enterococcus, and clinically important anaerobic organisms, including Bacteroides fragilis. This broad antibacterial spectrum suggested that cefoxitin might be an effective single antibiotic agent for the treatment of mixed aerobic-anaerobic infections in obstetric and gynecologic patients. In this investigation, the efficacy and safety of cefoxitin was evaluated in 109 patients, 68 with salpingitis, 25 with endomyometritis, 9 with pelvic cellulitis, and 7 with pelvic abscesses. An average of 2.5 bacteria were isolated from each patient. Aerobic bacteria alone were isolated in 38% of patients, anaerobic bacteria alone in 25%, and a combination of aerobic and anaerobic bacteria was isolated in 37% of patients. Overall, 100 of 109 (92%) infections responded to treatment with cefoxitin alone. The major cause of treatment failure was the presence of abscesses requiring surgical drainage. In addition to being an effective single agent for the management of pelvic infections, cefoxitin proved to be safe and well tolerated by patients.

Original languageEnglish (US)
Pages (from-to)193-198
Number of pages6
JournalObstetrics and Gynecology
Volume54
Issue number2
StatePublished - 1979

Fingerprint

Pelvic Infection
Cefoxitin
Aerobic Bacteria
Anaerobic Bacteria
Abscess
Therapeutics
Parametritis
Cephamycins
Salpingitis
Bacteria
Endometritis
Bacteroides fragilis
Enterobacter
Enterococcus
Gram-Positive Bacteria
Pseudomonas
Infection
Gram-Negative Bacteria
Treatment Failure
Obstetrics

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Cefoxitin : Single-agent treatment of mixed aerobic-anaerobic pelvic infections. / Sweet, Richard L; Ledger, W. J.

In: Obstetrics and Gynecology, Vol. 54, No. 2, 1979, p. 193-198.

Research output: Contribution to journalArticle

@article{e812206a63714ad68c0f105deaf59035,
title = "Cefoxitin: Single-agent treatment of mixed aerobic-anaerobic pelvic infections",
abstract = "Cefoxitin (mefoxin), a new semisynthetic cephamycin antibiotic, is resistant to degradation by β-lactamase enzymes produced by bacteria. In vitro, cefoxitin is active against virtually all clinically important gram-negative facultative bacteria other than Pseudomonas and Enterobacter spp., gram-positive aerobic bacteria other than the enterococcus, and clinically important anaerobic organisms, including Bacteroides fragilis. This broad antibacterial spectrum suggested that cefoxitin might be an effective single antibiotic agent for the treatment of mixed aerobic-anaerobic infections in obstetric and gynecologic patients. In this investigation, the efficacy and safety of cefoxitin was evaluated in 109 patients, 68 with salpingitis, 25 with endomyometritis, 9 with pelvic cellulitis, and 7 with pelvic abscesses. An average of 2.5 bacteria were isolated from each patient. Aerobic bacteria alone were isolated in 38{\%} of patients, anaerobic bacteria alone in 25{\%}, and a combination of aerobic and anaerobic bacteria was isolated in 37{\%} of patients. Overall, 100 of 109 (92{\%}) infections responded to treatment with cefoxitin alone. The major cause of treatment failure was the presence of abscesses requiring surgical drainage. In addition to being an effective single agent for the management of pelvic infections, cefoxitin proved to be safe and well tolerated by patients.",
author = "Sweet, {Richard L} and Ledger, {W. J.}",
year = "1979",
language = "English (US)",
volume = "54",
pages = "193--198",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Cefoxitin

T2 - Single-agent treatment of mixed aerobic-anaerobic pelvic infections

AU - Sweet, Richard L

AU - Ledger, W. J.

PY - 1979

Y1 - 1979

N2 - Cefoxitin (mefoxin), a new semisynthetic cephamycin antibiotic, is resistant to degradation by β-lactamase enzymes produced by bacteria. In vitro, cefoxitin is active against virtually all clinically important gram-negative facultative bacteria other than Pseudomonas and Enterobacter spp., gram-positive aerobic bacteria other than the enterococcus, and clinically important anaerobic organisms, including Bacteroides fragilis. This broad antibacterial spectrum suggested that cefoxitin might be an effective single antibiotic agent for the treatment of mixed aerobic-anaerobic infections in obstetric and gynecologic patients. In this investigation, the efficacy and safety of cefoxitin was evaluated in 109 patients, 68 with salpingitis, 25 with endomyometritis, 9 with pelvic cellulitis, and 7 with pelvic abscesses. An average of 2.5 bacteria were isolated from each patient. Aerobic bacteria alone were isolated in 38% of patients, anaerobic bacteria alone in 25%, and a combination of aerobic and anaerobic bacteria was isolated in 37% of patients. Overall, 100 of 109 (92%) infections responded to treatment with cefoxitin alone. The major cause of treatment failure was the presence of abscesses requiring surgical drainage. In addition to being an effective single agent for the management of pelvic infections, cefoxitin proved to be safe and well tolerated by patients.

AB - Cefoxitin (mefoxin), a new semisynthetic cephamycin antibiotic, is resistant to degradation by β-lactamase enzymes produced by bacteria. In vitro, cefoxitin is active against virtually all clinically important gram-negative facultative bacteria other than Pseudomonas and Enterobacter spp., gram-positive aerobic bacteria other than the enterococcus, and clinically important anaerobic organisms, including Bacteroides fragilis. This broad antibacterial spectrum suggested that cefoxitin might be an effective single antibiotic agent for the treatment of mixed aerobic-anaerobic infections in obstetric and gynecologic patients. In this investigation, the efficacy and safety of cefoxitin was evaluated in 109 patients, 68 with salpingitis, 25 with endomyometritis, 9 with pelvic cellulitis, and 7 with pelvic abscesses. An average of 2.5 bacteria were isolated from each patient. Aerobic bacteria alone were isolated in 38% of patients, anaerobic bacteria alone in 25%, and a combination of aerobic and anaerobic bacteria was isolated in 37% of patients. Overall, 100 of 109 (92%) infections responded to treatment with cefoxitin alone. The major cause of treatment failure was the presence of abscesses requiring surgical drainage. In addition to being an effective single agent for the management of pelvic infections, cefoxitin proved to be safe and well tolerated by patients.

UR - http://www.scopus.com/inward/record.url?scp=0018380661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018380661&partnerID=8YFLogxK

M3 - Article

C2 - 460753

AN - SCOPUS:0018380661

VL - 54

SP - 193

EP - 198

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2

ER -